Discontinuation and dose adjustment of metoprolol after metoprolol-paroxetine/fluoxetine co-prescription in Dutch elderly

The burden and management of cytochrome P450 2D6 (CYP2D6)-mediated drug-drug interaction (DDI): co-medication of metoprolol and paroxetine or fluoxetine in the elderly

(2017) Muh. Akbar Bahar et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Pharmacogenetics of drug–drug interaction and drug–drug–gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6

(2017) Muh Akbar Bahar et al.   PHARMACOGENOMICS

Relation between CYP2D6 Genotype, Phenotype and Therapeutic Drug Concentrations among Nortriptyline and Venlafaxine Users in Old Age Psychiatry

(2016) E. Berm et al.   PHARMACOPSYCHIATRY

Factors associated with β-blocker initiation and discontinuation in a population-based cohort of seniors newly diagnosed with heart failure

(2016) Jean-Pierre Gregoire et al.   Patient Preference and Adherence

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline forCYP2D6andCYP2C19Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

(2015) JK Hicks et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study

(2015) Aizati N. A. Daud et al.   DRUG SAFETY

Fluoxetine- and Norfluoxetine-Mediated Complex Drug–Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4

(2014) J E Sager et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians

(2014) K. P. Kerr et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy

(2013) Julie Doan et al.   ANNALS OF PHARMACOTHERAPY

The population-based prescription database IADB.nl: its development, usefulness in outcomes research and challenges

(2013) Sipke T Visser et al.   Expert Review of Pharmacoeconomics & Outcomes Research

Complete Atrioventricular Block Associated With Concomitant Use of Metoprolol and Paroxetine

(2012) Orhan Onalan et al.   MAYO CLINIC PROCEEDINGS

CYP2D6 genotype affects age-related decline in flecainide clearance

(2012) Kosuke Doki et al.   Pharmacogenetics and Genomics

Cytochrome P450-mediated cardiovascular drug interactions

(2011) André J Scheen   Expert Opinion on Drug Metabolism & Toxicology

A critical evaluation of clinical decision support for the detection of drug–drug interactions

(2011) Pamela L Smithburger et al.   Expert Opinion On Drug Safety

Effects of Paroxetine on the Pharmacokinetics and Pharmacodynamics of Immediate-Release and Extended-Release Metoprolol

(2011) Robert B Parker et al.   PHARMACOTHERAPY

Influence of Metoprolol Dosage Release Formulation on the Pharmacokinetic Drug Interaction With Paroxetine

(2010) Stephen M. Stout et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Toward Optimal Treatment in Women: The Effect of Sex on Metoprolol-Diphenhydramine Interaction

(2009) Ashish Sharma et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Drug safety alert generation and overriding in a large Dutch university medical centre

(2009) Heleen van der Sijs et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Influence of sex and CYP2D6 genotype on mirtazapine disposition, evaluated in Spanish healthy volunteers

(2009) Alberto M. Borobia et al.   PHARMACOLOGICAL RESEARCH

Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction

(2008) Roger K. Verbeeck   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY